Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice

Cardiovascular Pathology

Volumn 22, Issue 6, 2013, Pages 458-464

  Caravaggio, Justin W ^a   Hasu, Mirela ^a   MacLaren, Robin ^a   Thabet, Mohamed ^a   Raizman, Joshua E ^a   Veinot, John P ^a   Marcel, Yves L ^a   Milne, Ross W ^a   Whitman, Stewart C ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Amyloid; Atherosclerosis; Bone marrow transplantation; Insulin degrading enzyme; LDL receptor deficient mice; Receptor for advanced glycation end products (RAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; CHOLESTEROL; INSULINASE; LOW DENSITY LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BONE MARROW CELL; CELL LEVEL; CELL MIGRATION; CELL SURFACE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME DEFICIENCY; ENZYME SUBSTRATE; FEMALE; FOAM CELL; IRRADIATION; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECIPIENT; WILD TYPE;

AMYLOID; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; INSULIN-DEGRADING ENZYME; LDL RECEPTOR-DEFICIENT MICE; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE);

AMYLOID BETA-PEPTIDES; ANIMALS; AORTIC DISEASES; ATHEROSCLEROSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; FOAM CELLS; INSULYSIN; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LDL; SCAVENGER RECEPTORS, CLASS A; SEX FACTORS; TIME FACTORS;

EID: 84893663363     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2013.03.006     Document Type: Article

References (47)

1. Kzhyshkowska J, Neyen C, Gordon S. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 2012;217:492-502.
2. Makinen PI, Läppalainen JP, Heinonen SE, Leppänen P, Lähteenvuo MT, Aarnio JV, Heikkilä J, Turunen MP, Ylä-Herttuala S. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc Res 2010;88:530-8.
3. Zhu XD, Zhuang Y, Ben JJ, Qian LL, Huang HP, Bai H, Sha JH, He ZG, Chen Q. Caveloae-dependent endocytosis is required for class A macrophage scavenger receptor-mediated apoptosis in macrophages. J Biol Chem 2011;286:8231-9.
4. Miki S, Tsukada S, Nakamura Y, Aimoto S, Hojo H, Sato B, Yamamoto M, Miki Y. Functional and possible physical association of scavenger receptor with cytoplasmic tyrosine kinase Lyn in monocytic THP-1-derived macrophages. FEBS Lett 1996;399(3):241-4.
5. Sano H, Ishino M, Krämer H, Shimizu T, Mitsuzawa H, Nishitani C, Kuroki Y. The microtubule-binding protein Hook3 interacts with a cytoplasmic domain of scavenger receptor A. J Biol Chem 2007;282:7973-81.
6. Weirich G, Mengele K, Yfanti C, Gkazepis A, Hellmann D, Welk A, Giersig C, Kuo WL, Rosner MR, Tang WJ, Schmitt M. Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines. Biol Chem 2008;389(1441):1445.
7. Kuo WL, Montag AG, Rosner MR. Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. Endocrinology 1993;132:604-11.
8. Bennet RG, Hamel FG, Duckworth WC. Identification and isolation of a cytosolic proteolytic complex containing insulin degrading enzyme and the multicatalytic proteinase. Biochem Biophys Res Commun 1994;202:1047-53.
9. Yokono K, Roth RA, Baba S. Identification of insulin-degrading enzyme on the surface of cultured human lymphocytes, rat hepatoma cells, and primary cultures of rat hepatocytes. Endocrinology 1982;111:1102-8.
10. Hamel FG, Mahoney MJ, Duckworth WC. Degradation of intraendosomal insulin by insulin-degrading enzyme without acidification. Diabetes 1991;40:436-43.
11. Authier F, Bergeron J J M, Ou WJ, Rachubinski RA, Posner BI, Walton PA. Degradation of the cleaved leader peptide of thiolase by a peroxisomal proteinase. Proc Natl Acad Sci U S A 1995;92:3859-63.
12. Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J 2004;383:439-46.
13. Duckworth WC, Hamel FG, Bennett R, Ryan MP, Roth RA. Human red blood cell insulin-degrading enzyme and rat skeletal muscle insulin protease share antigenic sites and generate identical products from insulin. J Biol Chem 1990;265:2984-7.
14. Baumeister H, Müller D, Rehbein M, Richter D. The rat insulin-degrading enzyme. Molecular cloning and characterization of tissue-specific transcripts. FEBS Lett 1993;317:250-4.
15. Kayalar C, Wong WT. Metalloendoprotease inhibitors which block the differentiation of L6 myoblasts inhibit insulin degradation by the endogenous insulindegrading enzyme. J Biol Chem 1989;264:8928-34.
16. Kurochkin IV. Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. FEBS Lett 1998;427:153-6.
17. Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulindegrading enzyme. J Biol Chem 2000;275:36621-5.
18. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guénette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003;100:4162-7.
19. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 2004;164:1425-34.
20. Rose K, Savoy LA, Muir AV, Davies JG, Offord RE, Turcatti G. Insulin proteinase liberates from glucagon a fragment known to have enhanced activity against Ca2 + + Mg2+-dependent ATPase. Biochem J 1988;256:847-51.
21. Gu HF, Efendic S, Nordman S, Östenson CG, Brismar K, Brookes AJ, Prince JA. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. Diabetes 2004;53:2137-42.
22. Rudovich N, Pivovarova O, Fisher E, Fischer-Rosinsky A, Spranger J, Möhlig M, Schulze MB, Boeing H, Pfeiffer A F H. Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes. J Mol Med 2009;87:1145-51.
23. Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. Decreased catalytic activity of the insulindegrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 2007;282:7825-32.
24. Howlett GJ, Moore KJ. Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol 2006;17:541-7.
25. Babev VR, Ishiguro H, Ding L, Yancey PG, Dove DR, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF. Macrophage expression of peroxisome proliferator- activated receptor-a reduces atherosclerosis in low-density receptor-deficient mice. Circulation 2007;116:1404-12.
26. Kosswig N, Rice S, Daugherty A, Post SR. Class A scavenger receptor-mediated adhesion and internalization require distinct cytoplasmic domains. J Biol Chem 2003;278:34219-25.
27. De Meyer G R Y, De Cleen D M M, Cooper S, Knaapen WM, Jans DM, Martinet W, Herman AG, Bult H, Kockx MM. Platelet phagocytosis and processing of betaamyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res 2002;90:1197-204.
28. Li L, Cao D, Garber DW, Kim H, Fukuchi KI. Association of aortic atherosclerosis with cerebral β-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol 2003;163:2155-64.
29. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation end products (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009;11:e9.
30. Yan S-D, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91.
31. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH. Amyloid β interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 2009;182:5778-88.
32. Fazio S, Hasty AH, Carter KJ, Murray AB, Price JO, Linton MF. Leukocyte low density lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo: bone marrow transplantation studies in the mouse. J Lipid Res 1997;38:391-400.
33. Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K. Inflammatory NF-kB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production. Am J Physiol Gastrointest Liver Physiol 2009;296:G1287-98.
34. *3-Leiden mice. J Lipid Res 2011;52:942-50.
35. Bartolomé N, Arteta B, Martinez MJ, Chico Y, Ochoa B. Kupffer cell products and interleukin 1β directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes. Innate Immun 2008;14:255-66.
36. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with dietinduced insulin resistance. Diabetes 2009;58:2198-210.
37. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley G H K, Yang J, Miao F, Ross C J D, Van Eck M, Hayden MR, Van Nostrand W, St George-Hyslop P, Westaway D, Wellington CJ. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant Aβ in plasma. Neurobiol Dis 2006;24:114-27.
38. Ren M, Guo Q, Guo L, Lenz M, Qian F, Koenen RR, Xu H, Schilling AB, Weber C, Ye RD, Dinner AR, Tang WJ. Polymerization of MIP-1 chomokine (CCL3 adnCCL4) and clearance fo MIP-1 by insulin-degrading enzyme. EMBO J 2010;29:3952-66.
39. Kennedy A, Gruen ML, Gutierrez DA, Surmi B, Orr JS, Webb CD, Hasty AH. Impact of macrophage inflammatory protein-1a deficiency on atherosclerotic lesion formation, hepatic steatosis and adipose tissue expansion. PLoS ONE 2012;7(e31508):1-12.
40. Moore KJ, El Khoury JB, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW. A CD36-initiated signaling cascade mediates inflammatory effects of β-amyloid. J Biol Chem 2002;277:47373-9.
41. Puglielli L, Friedich AL, Setchell K D R, Nagano S, Opazo C, Cherny RA, Barnham KJ, Wade JD, Melov S, Kovacs DM, Bush AI. Alzheimer disease β-amyloid activity mimics cholesterol oxidase. J Clin Invest 2005;115:2556-63.
42. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amloid β peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996;271:32916-22.
43. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99.
44. Mackic JB, Stins MF, McComb JG, Calero M, Ghiso J, Sik-Kim K, Yan S-D, Stern D, Schmidt A-M, Frangione B, Zlokovic BV. Human blood-brain barrier receptors for Alzheimer's amyloid-β. 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 1998;102:734-43.
45. Medeiros LA, Khan R, El Khoury JB, Pham C L L, Hatters DM, Howlett GJ, Lopez R, O'Brien KD, Moore KJ. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem 2004;279:10643-8.
46. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 2012;42:1151-61.
47. Soro-Paavonen A, Watson A M D, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm K. RAGE deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-9.